KKR Gives Chinese Cord Blood Co. $65M Infusion

Law360, New York (April 12, 2012, 1:33 PM EDT) -- Private equity giant Kohlberg Kravis Roberts & Co. has signed up to give China's largest cord blood bank operator an injection of $65 million to help the company expand its services across the country, KKR announced Thursday.

The capital will come from KKR China Growth Fund LP in the form of senior unsecured convertible notes with a 7 percent interest rate. Per the deal, the private equity firm is entitled to place one of its members on China Cord Blood Corp.'s board of directors and to...
To view the full article, register now.